New England Journal of Medicine
Browse Interactive Medical Case from the New England Journal of Medicine.
Browse Interactive Medical Case from the New England Journal of Medicine.
The autologous cellular therapy exagamglogene autotemcel is generated by editing an erythroid-specific enhancer of BCL11A. Could another site be edited unintentionally? This study gauged the…
Quick Take Video Summary from The New England Journal of Medicine — FFR-Guided Complete PCI for STEMI
Subcutaneous administration of the monoclonal antibody L9LS protected adults against controlled Plasmodium falciparum infection in a phase 1 trial. Whether a monoclonal antibody administered subcut…
Recent approvals of exa-cel for treatment of sickle cell disease and transfusion-dependent β-thalassemia mark the dawn of the era of gene editing in medicine. But…
Abdominal pain and large-volume hematochezia developed in a man who was in the hospital for a ruptured cerebral aneurysm. Findings on endoscopy and colonoscopy were…
Subcutaneous administration of the monoclonal antibody L9LS protected adults against controlled Plasmodium falciparum infection in a phase 1 trial. Whether a monoclonal antibody administered subcut…
Review Article from The New England Journal of Medicine — Wearable Digital Health Technologies for Monitoring in Cardiovascular Medicine
Despite being absolutely clear that she wanted a quick, painless end of life, a geriatrician’s elderly mother receives aggressive care. How can we ensure that…
Recent approvals of exa-cel for treatment of sickle cell disease and transfusion-dependent β-thalassemia mark the dawn of the era of gene editing in medicine. But…
Exagamglogene autotemcel (exa-cel) is a nonviral cell therapy designed to reactivate fetal hemoglobin synthesis through ex vivo clustered regularly interspaced short palindromic repeats (CRISPR)–Ca…